Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
05:19pm, Wednesday, 05'th Jun 2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advi
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
11:00am, Wednesday, 05'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Inv
Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript)
01:22pm, Tuesday, 04'th Jun 2024
Moderna, Inc. (NASDAQ:MRNA ) Moderna Oncology Investor Event June 3, 2024 7:15 PM ET Company Participants Stephen Hoge - President Kyle Holen - Head of Development, Therapeutics and Oncology Michelle
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
11:12am, Tuesday, 04'th Jun 2024
Cancer vaccines are finally showing promise as Moderna and Merck touted promising data on an experimental skin cancer vaccine and the U.K. announced plans for a “landmark” scheme to test the techn
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Inv
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Inv
NEW YORK--(BUSINESS WIRE)---- $MRNA #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. (“Moderna” or
Moderna cancer vaccine's potential revealed in phase II data
10:48am, Monday, 03'rd Jun 2024
Data from a key cancer conference has underlined the potential of a vaccine for melanoma that has now moved into late-stage clinical trials here in the UK. Last month, we heard of the first dosing
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
10:46am, Monday, 03'rd Jun 2024
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product.
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
09:00am, Monday, 03'rd Jun 2024
Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin canc
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
08:23am, Monday, 03'rd Jun 2024
Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patient
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or d
Is Moderna Stock a Buy Now That It's a 2-Product Company?
06:07am, Monday, 03'rd Jun 2024
Moderna earned approval for mResvia, a respiratory syncytial virus vaccine, on May 31. Instead of soaring in response to the great news, Moderna stock fell.
Moderna secures a second FDA vaccine approval as Spikevax sales plummet
05:20am, Monday, 03'rd Jun 2024
Moderna announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults ages 60 and older. This will be the only RSV vaccine
Moderna Investors Just Got Some Bullish News
04:50am, Monday, 03'rd Jun 2024
Moderna has brought in billions of dollars in earnings thanks to its coronavirus vaccine. But demand for that product has declined, and that has worried investors.
